TipRanks
Tandem Diabetes Care (DE:TD5A)
FRANKFURT:TD5A
Germany Market
TD5A
Tandem Diabetes Care
RESEARCH TOOLSreports

Tandem Diabetes Care (TD5A) Stock Forecast & Price Target

3 Followers
See the Price Targets and Ratings of:

TD5A Analyst Ratings

Moderate Buy
14Ratings
Moderate Buy
8 Buy
6 Hold
0 Sell
Based on 14 analysts giving stock ratings to
Tandem
Diabetes Care
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

TD5A Stock 12 Month Forecast

Average Price Target

€23.89
▲(29.83% Upside)
Based on 14 Wall Street analysts offering 12 month price targets for Tandem Diabetes Care in the last 3 months. The average price target is €23.89 with a high forecast of €44.62 and a low forecast of €16.06. The average price target represents a 29.83% change from the last price of €18.40.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"9":"€9","18":"€18","27":"€27","36":"€36","45":"€45"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":44.618994,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€44.62</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":23.888322941538465,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€23.89</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":16.06283784,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€16.06</span>\n  </div></div>","useHTML":true}}],"tickPositions":[9,18,27,36,45],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,14.4,16.724538,19.049076,21.373614,23.698152,26.02269,28.347228,30.671765999999998,32.996304,35.320842,37.64538,39.969918,42.294456,{"y":44.618994,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,14.4,15.129870995502959,15.859741991005919,16.589612986508875,17.319483982011835,18.049354977514795,18.779225973017752,19.509096968520712,20.238967964023672,20.96883895952663,21.69870995502959,22.42858095053255,23.158451946035505,{"y":23.888322941538465,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,14.4,14.527910603076924,14.655821206153847,14.783731809230769,14.911642412307692,15.039553015384616,15.16746361846154,15.295374221538461,15.423284824615385,15.551195427692308,15.679106030769232,15.807016633846153,15.934927236923077,{"y":16.06283784,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":10.34,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.535,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.47,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.83,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.665,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.27,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.475,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.5,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.6,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.2,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.5,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.9,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.4,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target€44.62Average Price Target€23.89Lowest Price Target€16.06
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Mizuho Securities Analyst forecast on DE:TD5A
Anthony Petrone
Mizuho Securities
Mizuho Securities
€17.85→€16.06
Hold
-12.70%
Downside
Assigned
10/13/26
Tandem Diabetes price target lowered to $18 from $20 at MizuhoTandem Diabetes price target lowered to $18 from $20 at Mizuho
Barclays Analyst forecast on DE:TD5A
Christopher Pasquale
Barclays
Barclays
€16.06
Hold
-12.70%
Downside
Initiated
10/07/26
Barclays Keeps Their Hold Rating on Tandem Diabetes Care (TNDM)
Citi Analyst forecast on DE:TD5A
Joanne Wuensch
Citi
Citi
€21.42→€17.85
Hold
-3.00%
Downside
Reiterated
10/01/26
Citi cuts Tandem target, opens 'upside 90-day catalyst watch'Citi cuts Tandem target, opens 'upside 90-day catalyst watch'
RBC Capital Analyst forecast on DE:TD5A
Kendall Au
RBC Capital
RBC Capital
€23.2
Buy
26.10%
Upside
Reiterated
10/01/26
Tandem Diabetes Care (TNDM) Receives a Buy from RBC Capital
Lake Street Analyst forecast on DE:TD5A
Frank Takkinen
Lake Street
Lake Street
€44.62
Buy
142.49%
Upside
Reiterated
09/28/26
Analysts' Top Healthcare Picks: Tandem Diabetes Care (TNDM), Alterity Therapeutics (ATHE)
Truist Financial Analyst forecast on DE:TD5A
Richard Newitter
Truist Financial
Truist Financial
€27.66→€24.99
Buy
35.80%
Upside
Assigned
09/24/26
Analysts Are Bullish on These Healthcare Stocks: Mediwound (MDWD), BridgeBio Pharma (BBIO)
William Blair Analyst forecast on DE:TD5A
Steven Lichtman
William Blair
William Blair
―
Buy
―
Initiated
08/21/26
Tandem Diabetes initiated with an Outperform at William BlairTandem Diabetes initiated with an Outperform at William Blair
Canaccord Genuity Analyst forecast on DE:TD5A
William Plovanic
Canaccord Genuity
Canaccord Genuity
€35.7
Buy
94.00%
Upside
Reiterated
08/11/26
Tandem Diabetes Care: Buy Rating Reaffirmed on Transformation Momentum and Innovation Catalysts; $40 Price Target Maintained
Oppenheimer Analyst forecast on DE:TD5A
Unknown Analyst
Oppenheimer
Not Ranked
Oppenheimer
€19.63
Buy
6.70%
Upside
Assigned
08/07/26
Oppenheimer Sticks to Its Buy Rating for Tandem Diabetes Care (TNDM)
Stifel Nicolaus Analyst forecast on DE:TD5A
Jonathan Block
Stifel Nicolaus
Stifel Nicolaus
€19.63
Hold
6.70%
Upside
Reiterated
08/07/26
Stifel Nicolaus Reaffirms Their Hold Rating on Tandem Diabetes Care (TNDM)
Bank of America Securities Analyst forecast on DE:TD5A
Travis Steed
Bank of America Securities
Bank of America Securities
€22.31
Hold
21.25%
Upside
Reiterated
08/07/26
Analysts Offer Insights on NA Companies: Springer Nature AG & Co. KGaA (Other OTC: SPGDF), Lionsgate Studios (NYSE: LION) and Tandem Diabetes Care (NASDAQ: TNDM)
UBS Analyst forecast on DE:TD5A
Patrick Wood
UBS
UBS
€16.06
Hold
-12.70%
Downside
Reiterated
08/07/26
UBS Keeps Their Hold Rating on Tandem Diabetes Care (TNDM)
Piper Sandler Analyst forecast on DE:TD5A
Matthew O'Brien
Piper Sandler
Piper Sandler
€29.45
Buy
60.05%
Upside
Reiterated
08/07/26
Tandem Diabetes Care (TNDM) Gets a Buy from Piper Sandler
TD Cowen Analyst forecast on DE:TD5A
Mathew Blackman
TD Cowen
TD Cowen
€24.99
Buy
35.80%
Upside
Reiterated
08/06/26
Analyst Reiterates Buy on Tandem, Citing Building Momentum Ahead of Mobi Tubeless Launch and Improving Margins
Goldman Sachs Analyst forecast on DE:TD5A
David Roman
Goldman Sachs
Goldman Sachs
€18.74→€14.28
Hold
-22.40%
Downside
Reiterated
07/14/26
Tandem Diabetes Care (TNDM) Gets a Hold from Goldman Sachs
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Mizuho Securities Analyst forecast on DE:TD5A
Anthony Petrone
Mizuho Securities
Mizuho Securities
€17.85→€16.06
Hold
-12.70%
Downside
Assigned
10/13/26
Tandem Diabetes price target lowered to $18 from $20 at MizuhoTandem Diabetes price target lowered to $18 from $20 at Mizuho
Barclays Analyst forecast on DE:TD5A
Christopher Pasquale
Barclays
Barclays
€16.06
Hold
-12.70%
Downside
Initiated
10/07/26
Barclays Keeps Their Hold Rating on Tandem Diabetes Care (TNDM)
Citi Analyst forecast on DE:TD5A
Joanne Wuensch
Citi
Citi
€21.42→€17.85
Hold
-3.00%
Downside
Reiterated
10/01/26
Citi cuts Tandem target, opens 'upside 90-day catalyst watch'Citi cuts Tandem target, opens 'upside 90-day catalyst watch'
RBC Capital Analyst forecast on DE:TD5A
Kendall Au
RBC Capital
RBC Capital
€23.2
Buy
26.10%
Upside
Reiterated
10/01/26
Tandem Diabetes Care (TNDM) Receives a Buy from RBC Capital
Lake Street Analyst forecast on DE:TD5A
Frank Takkinen
Lake Street
Lake Street
€44.62
Buy
142.49%
Upside
Reiterated
09/28/26
Analysts' Top Healthcare Picks: Tandem Diabetes Care (TNDM), Alterity Therapeutics (ATHE)
Truist Financial Analyst forecast on DE:TD5A
Richard Newitter
Truist Financial
Truist Financial
€27.66→€24.99
Buy
35.80%
Upside
Assigned
09/24/26
Analysts Are Bullish on These Healthcare Stocks: Mediwound (MDWD), BridgeBio Pharma (BBIO)
William Blair Analyst forecast on DE:TD5A
Steven Lichtman
William Blair
William Blair
―
Buy
―
Initiated
08/21/26
Tandem Diabetes initiated with an Outperform at William BlairTandem Diabetes initiated with an Outperform at William Blair
Canaccord Genuity Analyst forecast on DE:TD5A
William Plovanic
Canaccord Genuity
Canaccord Genuity
€35.7
Buy
94.00%
Upside
Reiterated
08/11/26
Tandem Diabetes Care: Buy Rating Reaffirmed on Transformation Momentum and Innovation Catalysts; $40 Price Target Maintained
Oppenheimer Analyst forecast on DE:TD5A
Unknown Analyst
Oppenheimer
Not Ranked
Oppenheimer
€19.63
Buy
6.70%
Upside
Assigned
08/07/26
Oppenheimer Sticks to Its Buy Rating for Tandem Diabetes Care (TNDM)
Stifel Nicolaus Analyst forecast on DE:TD5A
Jonathan Block
Stifel Nicolaus
Stifel Nicolaus
€19.63
Hold
6.70%
Upside
Reiterated
08/07/26
Stifel Nicolaus Reaffirms Their Hold Rating on Tandem Diabetes Care (TNDM)
Bank of America Securities Analyst forecast on DE:TD5A
Travis Steed
Bank of America Securities
Bank of America Securities
€22.31
Hold
21.25%
Upside
Reiterated
08/07/26
Analysts Offer Insights on NA Companies: Springer Nature AG & Co. KGaA (Other OTC: SPGDF), Lionsgate Studios (NYSE: LION) and Tandem Diabetes Care (NASDAQ: TNDM)
UBS Analyst forecast on DE:TD5A
Patrick Wood
UBS
UBS
€16.06
Hold
-12.70%
Downside
Reiterated
08/07/26
UBS Keeps Their Hold Rating on Tandem Diabetes Care (TNDM)
Piper Sandler Analyst forecast on DE:TD5A
Matthew O'Brien
Piper Sandler
Piper Sandler
€29.45
Buy
60.05%
Upside
Reiterated
08/07/26
Tandem Diabetes Care (TNDM) Gets a Buy from Piper Sandler
TD Cowen Analyst forecast on DE:TD5A
Mathew Blackman
TD Cowen
TD Cowen
€24.99
Buy
35.80%
Upside
Reiterated
08/06/26
Analyst Reiterates Buy on Tandem, Citing Building Momentum Ahead of Mobi Tubeless Launch and Improving Margins
Goldman Sachs Analyst forecast on DE:TD5A
David Roman
Goldman Sachs
Goldman Sachs
€18.74→€14.28
Hold
-22.40%
Downside
Reiterated
07/14/26
Tandem Diabetes Care (TNDM) Gets a Hold from Goldman Sachs
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
KNSAKiniksa Pharmaceuticals
OMCLOmnicell
AXGNAxoGen
ONCBeOne Medicines
AHCOAdaptHealth
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Tandem Diabetes Care

3 Months
Matthew TaylorJefferies
Success Rate
6/10 ratings generated profit
60%
Average Return
+5.22%
Copying Matthew Taylor's trades and holding each position for 3 Months would result in 60.00% of your transactions generating a profit, with an average return of +5.22% per trade.
1 Year
Steven LichtmanWilliam Blair
Success Rate
21/29 ratings generated profit
72%
Average Return
+117.08%
Copying Steven Lichtman's trades and holding each position for 1 Year would result in 72.41% of your transactions generating a profit, with an average return of +117.08% per trade.
2 Years
Jeff JohnsonRobert W. Baird
Success Rate
10/17 ratings generated profit
59%
Average Return
+90.16%
Copying Jeff Johnson's trades and holding each position for 2 Years would result in 58.82% of your transactions generating a profit, with an average return of +90.16% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

TD5A Analyst Recommendation Trends

Rating
Jun 26
Jul 26
Aug 26
Sep 26
Oct 26
Strong Buy
8
8
4
6
6
Buy
4
2
7
6
6
Hold
11
12
11
9
8
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
23
22
22
21
20
In the current month, TD5A has received 12 Buy Ratings, 8 Hold Ratings, and 0 Sell Ratings. TD5A average Analyst price target in the past 3 months is 23.89.
Each month's total comprises the sum of three months' worth of ratings.

TD5A Financial Forecast

TD5A Earnings Forecast

Next quarter’s earnings estimate for TD5A is -€0.22 with a range of -€0.32 to -€0.15. The previous quarter’s EPS was -€0.27. TD5A beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year TD5A has Performed in-line its overall industry.
Next quarter’s earnings estimate for TD5A is -€0.22 with a range of -€0.32 to -€0.15. The previous quarter’s EPS was -€0.27. TD5A beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year TD5A has Performed in-line its overall industry.

TD5A Sales Forecast

Next quarter’s sales forecast for TD5A is €236.73M with a range of €234.20M to €240.16M. The previous quarter’s sales results were €226.31M. TD5A beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year TD5A has Performed in-line its overall industry.
Next quarter’s sales forecast for TD5A is €236.73M with a range of €234.20M to €240.16M. The previous quarter’s sales results were €226.31M. TD5A beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year TD5A has Performed in-line its overall industry.

TD5A Stock Forecast FAQ

What is DE:TD5A’s average 12-month price target, according to analysts?
Based on analyst ratings, Tandem Diabetes Care’s 12-month average price target is 23.89.
    What is DE:TD5A’s upside potential, based on the analysts’ average price target?
    Tandem Diabetes Care has 29.83% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Tandem Diabetes Care a Buy, Sell or Hold?
          Tandem Diabetes Care has a consensus rating of Moderate Buy, which is based on 8 buy ratings, 6 hold ratings and 0 sell ratings.
            What is Tandem Diabetes Care’s share price target?
            The average share price target for Tandem Diabetes Care is 23.89. This is based on 14 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is €44.62 ,and the lowest forecast is €16.06. The average share price target represents 29.83% Increase from the current price of €18.4.
              What do analysts say about Tandem Diabetes Care?
              Tandem Diabetes Care’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 14 Wall Streets Analysts.
                How can I buy shares of Tandem Diabetes Care?
                To buy shares of DE:TD5A, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.